39 related articles for article (PubMed ID: 35153798)
1. Design, synthesis and biological evaluation of rhein-piperazine-furanone hybrids as potential anticancer agents.
He Y; Zhang SS; Wei MX
RSC Med Chem; 2024 Mar; 15(3):848-855. PubMed ID: 38516604
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and cytotoxic activity of molecular hybrids based on quinolin-8-yloxy and cinnamide hybrids and their apoptosis inducing property.
Binjawhar DN; Al-Salmi FA; Abu Ali OA; Alghamdi MA; Fayad E; Saleem RM; Zaki I; Farouk NA
RSC Adv; 2024 Apr; 14(16):11443-11451. PubMed ID: 38595714
[TBL] [Abstract][Full Text] [Related]
3. Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment.
Ryad N; Elmaaty AA; M Ibrahim I; Ahmed Maghrabi AH; Yahya Alahdal MA; Saleem RM; Zaki I; Ghany LMAA
Future Med Chem; 2024 May; ():. PubMed ID: 38722235
[No Abstract] [Full Text] [Related]
4. Biological evaluation of novel amidino substituted coumarin-benzazole hybrids as promising therapeutic agents.
Beč A; Racané L; Žonja L; Persoons L; Daelemans D; Starčević K; Vianello R; Hranjec M
RSC Med Chem; 2023 May; 14(5):957-968. PubMed ID: 37252100
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization and
Qi XX; Wang PP; Cui LT; Jin M; Zhao LX; Li G
J Asian Nat Prod Res; 2024 Mar; ():1-12. PubMed ID: 38477295
[TBL] [Abstract][Full Text] [Related]
6. Two-carbon tethered artemisinin-isatin hybrids: design, synthesis, anti-breast cancer potential, and
Wang R; Huang R; Yuan Y; Wang Z; Shen K
Front Mol Biosci; 2023; 10():1293763. PubMed ID: 37928644
[TBL] [Abstract][Full Text] [Related]
7. Molecular Hybridization as a Strategy for Developing Artemisinin-Derived Anticancer Candidates.
Marchesi E; Perrone D; Navacchia ML
Pharmaceutics; 2023 Aug; 15(9):. PubMed ID: 37765156
[TBL] [Abstract][Full Text] [Related]
8. Metal-organic framework-encapsulated dihydroartemisinin nanoparticles induces apoptotic cell death in ovarian cancer by blocking ROMO1-mediated ROS production.
Yan Y; Yang X; Han N; Liu Y; Liang Q; Li LG; Hu J; Li TF; Xu Z
J Nanobiotechnology; 2023 Jun; 21(1):204. PubMed ID: 37386404
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of novel artemisinin-isatin hybrids with potential anti-leukemic cytotoxicity.
Wang P; Zhang Z; Cao W; Zhang X
Front Oncol; 2023; 13():1112369. PubMed ID: 37124527
[TBL] [Abstract][Full Text] [Related]
10. The Anti-Breast Cancer Activity of Dihydroartemisinin-5-methylisatin Hybrids Tethered via Different Carbon Spacers.
Yao Y; Wang H; Xu J; Gao F; Cao W
Molecules; 2022 Nov; 27(22):. PubMed ID: 36432095
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
Yang M; Liu H; Zhang Y; Wang X; Xu Z
Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and anti-breast cancer properties of butyric ester tethered dihydroartemisinin-isatin hybrids.
Zhao S; Zhang X; Tang M; Liu X; Deng J; Zhou W; Xu Z
Med Chem Res; 2023; 32(4):705-712. PubMed ID: 36816432
[TBL] [Abstract][Full Text] [Related]
13. The anti-breast cancer potential of dihydroartemisinin-isatin hybrids with hydrogen bond donors at C-3 position of isatin moiety.
Ding F; Chen X; Cao W; Dong T; Wang P
Fitoterapia; 2023 Mar; 165():105426. PubMed ID: 36608710
[TBL] [Abstract][Full Text] [Related]
14. Three-Carbon Linked Dihydroartemisinin-Isatin Hybrids: Design, Synthesis and Their Antiproliferative Anticancer Activity.
Dong M; Zheng G; Gao F; Li M; Zhong C
Front Pharmacol; 2022; 13():834317. PubMed ID: 35153798
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Anti-Lung Cancer Evaluation of 1, 2, 3-Triazole Tethered Dihydroartemisinin-Isatin Hybrids.
Hou H; Qu B; Su C; Hou G; Gao F
Front Pharmacol; 2021; 12():801580. PubMed ID: 34975498
[TBL] [Abstract][Full Text] [Related]
16. Artemisinin-isatin hybrids tethered via ethylene linker and their anti-lung cancer activity.
Wang R; Zhang Q; Chen M
Arch Pharm (Weinheim); 2023 Apr; 356(4):e2200563. PubMed ID: 36572639
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
